{"filing":{"accession_number":"0001104659-26-086685","cik":"0001649989","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-24","primary_document":"tm2621316d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_8k.htm"},"events":[{"id":20532,"run_id":18473,"accession_number":"0001104659-26-086685","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet AMD treatment, positioning it as the first and only FDA-approved ophthalmic bevacizumab formulation in the U.S. This is a major regulatory milestone and product approval event that enables commercial launch into an ~$8.5 billion market. While this is a significant operational and strategic achievement for the company, it does not fit neatly into the specific event categories (not earnings, M\u0026A, impairment, litigation, etc.) and is best classified as an operational milestone—a material regulatory approval and product launch event.","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19907,"accession_number":"0001104659-26-086685","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet AMD treatment, positioning it as the first and only FDA-approved ophthalmic bevacizumab formulation in the U.S. This is a major regulatory milestone and product approval event that enables commercial launch into an ~$8.5 billion market. While this is a significant operational and strategic achievement for the company, it does not fit neatly into the specific event categories (not earnings, M\u0026A, impairment, litigation, etc.) and is best classified as an operational milestone—a material regulatory approval and product launch event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T21:03:50.717933+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19907,"accession_number":"0001104659-26-086685","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet AMD treatment, positioning it as the first and only FDA-approved ophthalmic bevacizumab formulation in the U.S. This is a major regulatory milestone and product approval event that enables commercial launch into an ~$8.5 billion market. While this is a significant operational and strategic achievement for the company, it does not fit neatly into the specific event categories (not earnings, M\u0026A, impairment, litigation, etc.) and is best classified as an operational milestone—a material regulatory approval and product launch event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T21:03:50.717933+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-07-24"}]}